Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingfeiyin is a Traditional Chinese Medicine (TCM) decoction developed by the Affiliated Hospital of Changchun University of Traditional Chinese Medicine. It is primarily indicated for the treatment of pneumonia, including bacterial pneumonia, in pediatric patients. The formula is designed to clear heat and detoxify the lungs, a traditional approach to treating respiratory infections. Clinical investigation, such as trial ChiCTR2400080700, focuses on its ability to regulate the respiratory tract microbiome and its impact on the pathogenesis of pneumonia, suggesting a mechanism involving the restoration of microbial balance and reduction of pulmonary inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingfeiyin (Hospital Affiliated to Changchun University of Traditional Chinese Medicine).